Obesity and Cancer Risk: The Evolving Role of GLP-1s in Oncology
Experts discussed the integration of GLP-1 agonists and lifestyle interventions to mitigate obesity-related cancer risks and improve long-term survival.
Although clinicians widely recognize obesity as a modifiable risk factor, achieving and sustaining meaningful weight loss remains a complex challenge in the clinical setting. For decades, the oncology community has acknowledged the epidemiological links between elevated body mass index (BMI) and poor oncologic outcomes. However, translating that knowledge into actionable, effective, and sustainable clinical interventions has proven remarkably difficult. Patients frequently navigate a gauntlet of treatments, ranging from chemotherapy to multi-year endocrine regimens, that disrupt metabolic homeostasis, alter body composition, and actively promote weight gain.